公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2021 | Phase ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus pi3k inhibitor (alpelisib or buparlisib) for HR? advanced breast cancer | Tolaney S.M.; Im Y.-H.; Calvo E.; YEN-SHEN LU ; Hamilton E.; Forero-Torres A.; Bachelot T.; Maur M.; Fasolo A.; Tiedt R.; Nardi L.; Stammberger U.; Abdelhady A.M.; Ruan S.; Lee S.C. | Clinical Cancer Research | 14 | 10 | |
2018 | Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma | Bouattour M.; Raymond E.; Qin S.; ANN-LII CHENG ; Stammberger U.; Locatelli G.; Faivre S. | Hepatology | 181 | 172 |